The stock has a 36-month beta value of -6.80. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MNMD is 27.47M, and at present, short sellers hold a 25.21% of that float. On May 02, 2024, the average trading volume of MNMD was 2.29M shares.
MNMD) stock’s latest price update
The stock price of Mind Medicine Inc (NASDAQ: MNMD) has dropped by -0.95 compared to previous close of 9.52. Despite this, the company has seen a gain of 11.47% in its stock price over the last five trading days. InvestorPlace reported 2024-04-25 that Higher interest rates, pricier debt and an overemphasis on mega-caps over the past year mean that top small-cap stocks have played second fiddle to big-name giants like Nvidia (NASDAQ: NVDA ). But tides seem to be turning as investors increasingly seek diversification away from a handful of high-multiple tech stocks and toward a more diverse array of product types, operational structures and size — all of which small-cap stocks have in spades.
MNMD’s Market Performance
MNMD’s stock has risen by 11.47% in the past week, with a monthly drop of -4.26% and a quarterly rise of 144.30%. The volatility ratio for the week is 6.88% while the volatility levels for the last 30 days are 9.09% for Mind Medicine Inc The simple moving average for the last 20 days is -2.63% for MNMD’s stock, with a simple moving average of 93.62% for the last 200 days.
Analysts’ Opinion of MNMD
Many brokerage firms have already submitted their reports for MNMD stocks, with Leerink Partners repeating the rating for MNMD by listing it as a “Outperform.” The predicted price for MNMD in the upcoming period, according to Leerink Partners is $20 based on the research report published on April 15, 2024 of the current year 2024.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see MNMD reach a price target of $9. The rating they have provided for MNMD stocks is “Buy” according to the report published on December 05th, 2023.
ROTH Capital gave a rating of “Buy” to MNMD, setting the target price at $25 in the report published on December 09th of the previous year.
MNMD Trading at 10.29% from the 50-Day Moving Average
After a stumble in the market that brought MNMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.83% of loss for the given period.
Volatility was left at 9.09%, however, over the last 30 days, the volatility rate increased by 6.88%, as shares sank -19.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +86.00% upper at present.
During the last 5 trading sessions, MNMD rose by +11.47%, which changed the moving average for the period of 200-days by +122.41% in comparison to the 20-day moving average, which settled at $9.57. In addition, Mind Medicine Inc saw 157.65% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MNMD starting from Barrow Robert, who sale 16,519 shares at the price of $9.50 back on Mar 25 ’24. After this action, Barrow Robert now owns 580,202 shares of Mind Medicine Inc, valued at $156,930 using the latest closing price.
Karlin Dan, the Chief Medical Officer of Mind Medicine Inc, sale 6,578 shares at $9.50 during a trade that took place back on Mar 25 ’24, which means that Karlin Dan is holding 358,452 shares at $62,491 based on the most recent closing price.
Stock Fundamentals for MNMD
The total capital return value is set at -1.05. Equity return is now at value -83.59, with -65.01 for asset returns.
Based on Mind Medicine Inc (MNMD), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -4.5. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -75.18.
Currently, EBITDA for the company is -90.7 million with net debt to EBITDA at 0.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.22.
Conclusion
To sum up, Mind Medicine Inc (MNMD) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
